抗炎疗法在心力衰竭治疗中的潜在作用
Mohammed Kallash1, William H Frishman2,3
1From the Department of Medicine, Montefiore Medical Center, Bronx, NY.
Cardiology in review
|January 8, 2026
概括
炎症在心力衰竭 (HF) 发病过程中起着关键作用. 目前正在研究用新型疗法向炎细胞和炎症通路,以改善HF患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 生物医学科学 生物医学科学
背景情况:
- 心力衰竭 (HF) 是全球主要的健康负担,治疗进展有限.
- 了解高压机制对于开发有效治疗方法至关重要.
- 新出现的证据强调了炎症在HF发育和进展中的重要作用.
研究的目的:
- 研究炎症和炎症酶在心力衰竭病原发生中的作用.
- 评估抗炎疗法的有效性,包括针对炎症体的新药,用于治疗高血压.
- 阐明针对炎症途径的潜力,以改善HF发病率和死亡率的好处.
主要方法:
- 审查最近的证据,确定炎症在HF中的作用.
- 针对心脏压力因素 (如心肌梗塞和压力过载) 的炎症酶激活的分析.
- 对HF患者的抗炎疗法的临床试验数据的检查.
主要成果:
- 炎症酶激活和随后的细胞因子产生有助于心肌细胞功能障碍,纤维化和HF的不良心脏重塑.
- 由氧化应激,代谢问题和神经激素激活引起的慢性炎症加剧了HF.
- 之前对抗炎症药物的小试验在HF中产生了不确定的结果,需要进行更大的研究.
结论:
- 炎症过程是心力衰竭病理生理学的常见途径.
- 向炎酶和相关的炎症媒介体是对高频率的有前途的治疗策略.
- 较大的临床试验至关重要,以证实抗炎疗法在治疗心力衰竭方面的益处.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
Heart Failure Drugs: β-Blockers
758
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
758
Heart Failure VI: Adjunct Therapies
246
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
246
Heart Failure V: Medical Management
209
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
209
Heart Failure Drugs: Diuretics
789
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
789
Myocarditis III: Medical Management
168
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
168

